Payment overview · 2025
General Payments
$4,353.32
80 reported records · 19 companies
Healthcare provider profile · identity verified
Muhammad Rizwan Sardar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CANTON, OH · NPI 1891029658
Verified facts
What the public records show
CMS Open Payments records show Muhammad Rizwan Sardar, M.D. received $4,353.32 in general payments during 2025 across 80 reported records.
Abbott Laboratories accounted for 39.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,733.99 | 39.8% | 14 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $628.05 | 14.4% | 16 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$575.39 | 13.2% | 17 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $463.99 | 10.7% | 7 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $144.60 | 3.3% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $143.15 | 3.3% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $125.17 | 2.9% | 6 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $103.35 | 2.4% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $96.35 | 2.2% | 2 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $84.36 | 1.9% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $49.35 | 1.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $48.95 | 1.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.18 | 0.7% | 2 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $26.17 | 0.6% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $22.36 | 0.5% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $21.49 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.71 | 0.4% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $18.60 | 0.4% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $17.11 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,353.32 | 79 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,000.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $1,000.00 | 1 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $463.99 | 7 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $245.10 | 4 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $185.96 | 3 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $152.18 | 5 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $144.60 | 4 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $130.61 | 2 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $120.94 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $118.76 | 3 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $103.35 | 1 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $102.19 | 1 | 2025 |
Source payment records
|
|||||
| VENACURE 1470 PRO Normalized: venacure 1470 pro |
Device | AngioDynamics, Inc. | $96.35 | 2 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $84.36 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER TORQVUE 45 X 45 Normalized: amplatzer torqvue 45 x 45 |
Device | Abbott Laboratories | $81.98 | 2 | 2025 |
Source payment records
|
|||||
| SAVVYWIRE Normalized: savvywire |
Device | CARDIVA MEDICAL, INC. | $62.18 | 3 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $61.09 | 3 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $49.35 | 1 | 2025 |
Source payment records
|
|||||
| LM Undivided Normalized: lm undivided |
Device | Philips North America LLC | $48.95 | 1 | 2025 |
Source payment records
|
|||||
| OPTOWIRE Normalized: optowire |
Device | CARDIVA MEDICAL, INC. | $43.20 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.18 | 2 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER AAA Endoprosthesis Normalized: gore excluder aaa endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $26.17 | 1 | 2025 |
Source payment records
|
|||||
| NITREX Normalized: nitrex |
Device | Medtronic, Inc. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| NANOCROSS ELITE Normalized: nanocross elite |
Device | Medtronic, Inc. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| CONCERTOTM Normalized: concertotm |
Device | Medtronic, Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| HELI-FX ENDOANCHOR SYSTEM Normalized: heli fx endoanchor system |
Device | Medtronic, Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| GUIDELINER Normalized: guideliner |
Device | Teleflex LLC | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $13.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
229 | 60 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 617 | 169 |
| Clopidogrel | Clopidogrel Bisulfate | 505 | 157 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 79 |
| Eliquis | Apixaban | 229 | 60 |
| Furosemide | Furosemide | 203 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 201 | 65 |
| Xarelto | Rivaroxaban | 170 | 40 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 167 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 111 | 39 |
| Losartan Potassium | Losartan Potassium | 97 | 38 |
| Carvedilol | Carvedilol | 89 | 28 |
| Nitroglycerin | Nitroglycerin | 89 | 59 |
| Potassium Chloride | Potassium Chloride | 73 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 29 |
| Cilostazol | Cilostazol | 67 | 17 |
| Entresto | Sacubitril/Valsartan | 61 | 16 |
| Lisinopril | Lisinopril | 59 | 20 |
| Colchicine | Colchicine | 53 | 13 |
| Prasugrel Hcl | Prasugrel Hcl | 53 | 20 |
| Brilinta | Ticagrelor | 47 | 20 |
| Chlorthalidone | Chlorthalidone | 45 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 39 | 17 |
| Enoxaparin Sodium | Enoxaparin Sodium | 38 | 30 |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 23 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Prednisone | Prednisone | 20 | 15 |
| Metolazone | Metolazone | 18 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,353.32 · 80 records | Abbott Laboratories | ABRE, AMPLATZER AMULET, AMPLATZER TORQVUE 45 X 45, Barostim Neo System, CAMZYOS, CARDIOMEMS, CARDIVA VASCADE MVP VVCS 6-12F, CLOT MANAGEMENT, CONCERTOTM, COROFLOW, DRAGONFLY OPSTAR, ENDOCROSS Device, ENDURANT IIS, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, GORE EXCLUDER AAA Endoprosthesis, GUIDELINER, HAWKONE, HELI-FX ENDOANCHOR SYSTEM, IN.PACT ADMIRAL, Indigo System, LIMFLOW SYSTEM, LM Undivided, MICRA, NANOCROSS ELITE, NAVITOR, NITREX, OPSUMIT, OPTOWIRE, REPATHA, SAVVYWIRE, SYMPLICITY G3, Torus Stent Graft System, UPTRAVI, VENACURE 1470 PRO, WatchPATONE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error